In the News

Share
1667 News Items found
Dr. Bob Li
Medical Oncologist Bob Li Featured in the Presidential Symposium at the 2020 World Conference on Lung Cancer
Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS.
MSK immunologist Ming Li
Sloan Kettering Institute Scientists Solve a 100-Year-Old Mystery about Cancer
Scientists have long known that cancer cells and immune cells have an uncommon hunger for glucose but haven’t understood why. A new study offers an answer.
Lorenz Studer and Viviane Tabar
Upcoming Clinical Trial Will Test New Cell Therapy for Parkinson’s Disease in Humans
Study will be the first clinical trial testing an investigational stem cell therapy aimed at restoring lost brain cells called neurons in people with advanced Parkinson’s disease (PD).
Finding
Vijai Joseph and Sabine Topka in the lab
Repairing DNA Damage in Cancer Cells
New findings could lead to a different kind of cancer drug that targets a DNA damage repair pathway called nucleotide excision repair.
Francisco Sánchez-Rivera
Confronting a Crisis: How MSK Cancer Geneticists Responded to COVID-19
During World War II, US factories famously converted their operations to support the war effort. COVID-19 instigated something similar among cancer scientists.
Martin S. Tallman, MD
Memorial Sloan Kettering’s Martin S. Tallman, MD, Named American Society of Hematology President
Dr. Tallman will serve a year-long term as President for the American Society of Hematology.
Pediatric oncologist Nai-Kong Cheung
Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma
The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.
Memorial Sloan Kettering developmental biologist Luis Parada
Decoding the Biology of Brain Tumors
Brain cancer is deadly because it’s so difficult to study. Scientist Luis Parada has developed an innovative model to analyze how brain tumors form and respond to treatment.
Fiona and Stanley Druckenmiller
Donors on a Mission to Fast-Track Cancer Therapies at MSK
Meet Fiona and Stanley Druckenmiller, whose latest venture supports promising new avenues of research for experts at Memorial Sloan Kettering Cancer Center.
Luis Alberto Diaz Jr.
Luis Diaz’s Vision: Treating Cancer Earlier — Even Before It Develops
Luis Alberto Diaz, Jr. has dedicated his life’s work to addressing some of the most pressing challenges in cancer research — driven by one clear aim.
SKI immunologist Justin Perry holding a fish
Meet Justin Perry, a “Card-Carrying Alaskan” Whose Love for Science Took Him on an Unexpected Journey
Read an interview with Sloan Kettering Institute immunologist Justin Perry.
Stacia Smart and Owen Strong
Owen and Stacia: A Love Story
Discover how cyclist Stacia Smart turned her grief into purpose after her boyfriend died of a brain tumor.
Memorial Sloan Kettering physician-scientist Vinod Balachandran.
Taking Aim at Pancreatic Cancer: Reasons to Be Optimistic
MSK researchers are making important inroads in understanding and treating pancreatic cancer.
Sam Frackowiak, part of the Radiochemistry and Molecular Imaging Probe Core Facility, operates a robotic arm to prepare a radioactive theranostic drug that will seek out and destroy cancer cells.
Theranostics: A Smart Bomb for Cancer
When Dave Norkin was diagnosed at 39 with a rare cancer, he was told he had just months to live. Now, a decade later, he’s surviving — thanks to the emerging field of theranostics, which combines imaging and therapy for a search-and-destroy mission.
Craig B. Thompson, President and Chief Executive Officer of Memorial Sloan Kettering
To Our MSK Community
A generous gift provides a major boost to translational research at MSK.
Photo of a man, woman, and child sitting outside smiling
Translating Science Into Cures: Bringing Fresh Hope to the Denisiuk Family
Mark Denisiuk was diagnosed with acute myeloid leukemia in the spring of 2021. He found hope when he enrolled in an early trial of an entirely new kind of drug that’s based on lab research conducted at MSK.
Memorial Sloan Kettering patient Rebecca Lerner smiling in the hospital
Unlocking a Mystery: What’s Behind the Rise In Colorectal Cancer Among Young People
Doctors and scientists at MSK are desperately trying to figure out why more young patients like Rebecca, 33, are getting colorectal cancer — and how best to treat them.
A Fred’s Team runner giving a high five
Your Impact: Celebrating Our Donors’ Support in 2021
Learn about how our donor community is funding life-changing cancer research at Memorial Sloan Kettering and ensuring a brighter future for people with cancer around the world.
Dana Pe'er
“Beautiful Patterns in Biology”: How SKI’s Dana Pe’er Earned a Top Honor and Advocates for Women Scientists
Read an interview with Sloan Kettering Institute Computational and Systems Biology Chair Dana Pe'er.
Physician-scientist Nai-Kong Cheung
Caging the Beast: MSK Researchers Design a New Radiation Treatment More Destructive to Cancer Cells
Learn about the work of Nai-Kong Cheung and other MSK scientists who have learned more about how to deliver stronger treatment with less toxicity.